Murdoch, up close and personal – Reuters Blogs
Reuters landed its first exclusive interview with News Corp. kingpin Rupert Murdoch since agreeing to buy Dow Jones.
Aaron Roe(bot) Fulkerson Open source entrepreneur and digital viking.
About Me
I am a founder and the Chief Executive Officer of MindTouch, a popular open source business application and collaboration platform used by millions. Read more.
Murdoch could use a good ass kicking
September 13, 2007 — Aaron FulkersonFEMA Bans Photos of the Dead
September 8, 2005 — Aaron FulkersonNEW YORK Forced to defend what some critics consider its slow response to the devastation caused by Hurricane Katrina, the Federal Emergency Management Agency said on Tuesday it does not want the news media to take photographs of the dead as they are recovered from New Orleans.
FEMA, which is leading the rescue efforts, rejected requests from journalists to accompany rescue boats as they went out to search for storm victims, Reuters reported.
A FEMA spokeswoman told the wire service that space was needed on the rescue boats and assured Reuters that “the recovery of the victims is being treated with dignity and the utmost respect.”
“We have requested that no photographs of the deceased be made by the media,” the spokeswoman told Reuters via e-mail.
…”By and large, American television is the most sanitized television in the world,” he said. “They are less likely to show bodies, they are less likely to show graphic images of the dead than any television in the world.”
German Team Finds New Way to Block HIV Replication
January 18, 2005 — Aaron FulkersonGerman scientists have found a new way to prevent the HIV virus from replicating, offering hope in the face of the virus’s increasing resistance to existing drugs.
Joachim Hauber, a professor at the Heinrich-Pette Institute in Hamburg, told Reuters on Tuesday his team had identified a protein in human cells that the HIV virus uses to reproduce and run tests on a chemical that blocks this protein’s action.
Drugs such as GlaxoSmithKline’s AZT and existing inhibitors produce drug resistance because they work on viral proteins, which can mutate when the HIV virus replicate.
